Your browser doesn't support javascript.
loading
Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses.
Hellgren, Fredrika; Cagigi, Alberto; Arcoverde Cerveira, Rodrigo; Ols, Sebastian; Kern, Theresa; Lin, Ang; Eriksson, Bengt; Dodds, Michael G; Jasny, Edith; Schwendt, Kim; Freuling, Conrad; Müller, Thomas; Corcoran, Martin; Karlsson Hedestam, Gunilla B; Petsch, Benjamin; Loré, Karin.
Afiliação
  • Hellgren F; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Cagigi A; Center of Molecular Medicine, Stockholm, Sweden.
  • Arcoverde Cerveira R; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Ols S; Center of Molecular Medicine, Stockholm, Sweden.
  • Kern T; Nykode Therapeutics, Oslo, Norway.
  • Lin A; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Eriksson B; Center of Molecular Medicine, Stockholm, Sweden.
  • Dodds MG; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Jasny E; Center of Molecular Medicine, Stockholm, Sweden.
  • Schwendt K; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Freuling C; Center of Molecular Medicine, Stockholm, Sweden.
  • Müller T; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Corcoran M; Center of Molecular Medicine, Stockholm, Sweden.
  • Karlsson Hedestam GB; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Petsch B; Astrid Fagraeus Laboratory, Comparative Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Loré K; Certara USA, Inc, Princeton, NJ, USA.
Nat Commun ; 14(1): 3713, 2023 06 22.
Article em En | MEDLINE | ID: mdl-37349310
Licensed rabies virus vaccines based on whole inactivated virus are effective in humans. However, there is a lack of detailed investigations of the elicited immune response, and whether responses can be improved using novel vaccine platforms. Here we show that two doses of a lipid nanoparticle-formulated unmodified mRNA vaccine encoding the rabies virus glycoprotein (RABV-G) induces higher levels of RABV-G specific plasmablasts and T cells in blood, and plasma cells in the bone marrow compared to two doses of Rabipur in non-human primates. The mRNA vaccine also generates higher RABV-G binding and neutralizing antibody titers than Rabipur, while the degree of somatic hypermutation and clonal diversity of the response are similar for the two vaccines. The higher overall antibody titers induced by the mRNA vaccine translates into improved cross-neutralization of related lyssavirus strains, suggesting that this platform has potential for the development of a broadly protective vaccine against these viruses.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Raiva / Vírus da Raiva / Vacina Antirrábica Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Raiva / Vírus da Raiva / Vacina Antirrábica Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article